XML 115 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 775,778 $ 566,204
Short-term investments 915,317 931,718
Accounts receivable, net 835,279 574,810
Current portion of deferred commissions 175,039 139,890
Prepaid expenses and other current assets 125,488 132,071
Total current assets 2,826,901 2,344,693
Deferred commissions, less current portion 333,448 282,490
Long-term investments 1,013,332 581,856
Property and equipment, net [1] 468,085 347,216
Operating lease right-of-use assets [1] 402,428 0
Intangible assets, net 143,850 100,582
Goodwill 156,756 148,845
Deferred tax assets 599,633 20,642
Other assets 77,997 52,816
Total assets 6,022,430 3,879,140 [1]
Current liabilities:    
Accounts payable 52,960 30,733
Accrued expenses and other current liabilities [1] 461,403 330,246
Current portion of deferred revenue 2,185,754 1,651,594
Current portion of operating lease liabilities [1] 52,668 0
Total current liabilities 2,752,785 2,012,573
Deferred revenue, less current portion 40,038 38,597
Operating lease liabilities, less current portion [1] 383,221 0
Convertible senior notes, net 694,981 661,707
Other long-term liabilities [1] 23,464 55,064
Total liabilities 3,894,489 2,767,941
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued or outstanding 0 0
Common stock $0.001 par value; 600,000 shares authorized; 189,461 and 180,175 shares issued and outstanding at December 31, 2019 and 2018, respectively 189 180
Additional paid-in capital 2,454,741 2,093,834
Accumulated other comprehensive income (loss) 25,255 (4,035)
Accumulated deficit [1] (352,244) (978,780)
Total stockholders’ equity 2,127,941 1,111,199
Total liabilities and stockholders’ equity $ 6,022,430 $ 3,879,140
[1]
We adopted Topic 842 using the modified retrospective method as of January 1, 2019 and elected the transition option that allows us not to restate the comparative periods in our consolidated financial statements in the year of adoption. Refer to Note 2 for further details.